Updated February 19, 2017. There's no right way to study in college. Even students who have the same majors and take the same classes won't need to spend the same amount of time on coursework, because everyone has their own way of learning.
New Arthritis Drug Xeljanz Gets FDA Approval. Nov. 6, 2012 -- The FDA has approved Pfizer's Xeljanz (tofacitinib), a first-of-its-kind treatment for rheumatoid arthritis. Xeljanz is approved for use by patients not helped by methotrexate, the usual first treatment for RA. It's a pill taken twice a day. Xeljanz is a type of drug called a Janus kinase or JAK inhibitor. Blocking JAK mutes the inflammation responses responsible for RA.
In 2012, the FDA approved tofacitinib (Xeljanz) a new type of disease-modifying arthritis drug (DMARD). Tofacitinib is approved for patients with moderate-to-severe rheumatoid arthritis who have not been helped by methotrexate.Tofacitinib is the first new DMARD approved in over a decade.ntroduction. Rheumatoid arthritis (RA) is a chronic disease in which various joints in the body are inflamed, leading to swelling, pain, stiffness, and the possible loss of function. Rheumatoid arthritis is an autoimmune disease in which the body's immune system attacks joints and other tissues.